<DOC>
	<DOCNO>NCT01642758</DOCNO>
	<brief_summary>Beta thalassemia intermedia syndromes genetic anemia cause mutation reduce production beta globin , major component adult hemoglobin A , protein delivers oxygen throughout body . Patients suffer poor growth , fatigue , heart failure , endocrine deficiency , eventually , many require chronic blood transfusion . There approve therapeutic deficiency beta globin chain beta thalassemia . This trial study oral therapeutic stimulates production fetal globin , alternate type produce human , normally switched infancy . This type globin compensate miss protein beta thalassemia .</brief_summary>
	<brief_title>Trial HQK-1001 Beta Thalassemia Intermedia Lebanon</brief_title>
	<detailed_description>This trial experimental oral medicine stimulate production fetal hemoglobin , innate type hemoglobin normally make suppressed infancy . Fetal globin ( HbF ) perform function miss beta globin reduce anemia beta thalassemia , produce high amount normal . In trial , 10 patient beta thalassemia intermedia Lebanon receive study drug 6 month dose previously show safe normal volunteer beta thalassemia sickle cell patient stimulate fetal globin production many , give brief period . The purpose trial follow : 1 . To determine total hemoglobin level increase baseline subject study drug take 26 week . 2 . To determine fetal globin increase baseline level proportion subject study drug take 26 week . 3 . To determine number adverse event occur 26 week administration study drug beta thalassemia intermedia subject . After screen period , subject take study drug home day . They see every 4 week examination laboratory test dose period 4 week afterwards . This trial provide important step evaluate potential treatment patient beta thalassemia intermedia , use around world , effective safe .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<criteria>Diagnosis beta thalassemia intermedia Ages 1650 year Average total Hgb level 6.0 9.0 gm/dl within 30 day initial dose study drug Able comply study procedure If female childbearing potential , must document negative pregnancy test prior entry every 4 week Red blood cell transfusion within 3 month prior administration study drug QT Segment correct ( QTc ) &gt; 450 msec Use Erythropoiesis Stimulating Agents ( ESAs ) within 9 day first dose Hydroxyurea treatment within 6 month first study drug History significant arrythmias , syncope , resuscitation Alanine Transaminase ( ALT ) &gt; 4x upper limit normal Serum creatinine &gt; 1.5 mg/dl Sse iron chelate agent within 7 day first dose Pulmonary hypertension require oxygen therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Thalassemia intermedia</keyword>
	<keyword>Fetal hemoglobin</keyword>
	<keyword>Hemoglobin</keyword>
</DOC>